📇 Rhumatologue ·

M YVES LE BOUC

Pourquoi vous devez consulter ce praticien

3 raisons identifiées

Auteur de référence en rhumatologie
26 articles scientifiques publiés — un praticien à la pointe de la recherche
Encadrant universitaire
Forme la prochaine génération de rhumatologues (6 thèses dirigées)
Référence presse grand public
Cité 3 fois dans les médias — pédagogie reconnue

Rhumatologue

RPPS 10000303601

Enseignement

📊 Reconnaissance scientifique : 59/100📝 295 articles publiés🇫🇷 Publications académiques françaises (8)🎓 6 thèses dirigées

✨ Génération du profil synthétique IA en cours…

Direction de thèses

🎓 6 thèses dirigées

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Expert consensus document: Clinical and molecular diagnosis, screening and management of Beckwith-Wiedemann syndrome: an international consensus statement

Nature reviews. Endocrinology · 2018

📚 426 citations🎯 RCR 18.59Top 1% NIH🔓 Open Access📄 PDF gratuit ↗

Genetic disruption of the oncogenic HMGA2-PLAG1-IGF2 pathway causes fetal growth restriction

Genetics in medicine : official journal of the American College of Medical Genetics · 2018

📚 107 citations🎯 RCR 4.74Top 8% NIH🔓 Open Access📄 PDF gratuit ↗

Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016

📚 100 citations🎯 RCR 3.23Top 15% NIH🩺 Clinique🔓 Open Access

Lire l'abstract Crossref ↓

Purpose Wilms tumor (WT) is the most common pediatric renal tumor. Treatment planning under International Society of Paediatric Oncology (SIOP) protocols is based on staging and histologic assessment of response to preoperative chemotherapy. Despite high overall survival (OS), many relapses occur in patients without specific risk factors, and many successfully treated patients are exposed to treatments with significant risks of late effects. To investigate whether molecular biomarkers could improve risk stratification, we assessed 1q status and other potential copy number biomarkers in a large WT series. Materials and Methods WT nephrectomy samples from 586 SIOP WT 2001 patients were analyzed using a multiplex ligation-dependent probe amplification (MLPA) assay that measured the copy number of 1q and other regions of interest. Results One hundred sixty-seven (28%) of 586 WTs had 1q gain. Five-year event-free survival (EFS) was 75.0% in patients with 1q gain (95% CI, 68.5% to 82.0%) and 88.2% in patients without gain (95% CI, 85.0% to 91.4%). OS was 88.4% with gain (95% CI, 83.5% to 93.6%) and 94.4% without gain (95% CI, 92.1% to 96.7%). In univariable analysis, 1q gain was associated with poorer EFS (P < .001; hazard ratio, 2.33) and OS (P = .01; hazard ratio, 2.16). The association of 1q gain with poorer EFS retained significance in multivariable analysis adjusted for 1p and 16q loss, sex, stage, age, and histologic risk group. Gain of 1q remained associated with poorer EFS in tumor subsets limited to either intermediate-risk localized disease or nonanaplastic localized disease. Other notable aberrations associated with poorer EFS included MYCN gain and TP53 loss. Conclusion Gain of 1q is a potentially valuable prognostic biomarker in WT, in addition to histologic response to preoperative chemotherapy and tumor stage.

Cookies & analyse de trafic

M YVES LE BOUC

Pourquoi vous devez consulter ce praticien

Direction de thèses

Activité de recherche & publications

Publications académiques en France

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Articles de presse (3)

Top publications · les plus citées

Publications scientifiques (26) — classées par pathologie

Transversal13

Pédiatrie5

Épidémiologie & registres2

Génétique2

Activité physique / Rééducation1

Biomarqueurs / Auto-Ac1

Gériatrie1

IA en rhumatologie1

Pharmacovigilance1

Recommandations1

Partager cette fiche